Attend the FierceBiotech 3rd Drug Development Forum!
The leading executive-level forum for biotech strategy & networking | Oct 1-3 | Boston
HitGen has formed a drug discovery research collaboration with Boehringer Ingelheim to identify novel small-molecule leads.
Bay Area drug discovery company Verge Genomics has formed industry and academic alliances in neuro disorders.
Part of an international initiative, a pan-European observational study aims to improve clinical care of traumatic brain injury.
Clinerion inks a new deal that adds 60 million U.S. patients to its clinical trial patient recruitment system.
Charles River builds in vitro 3D tumor microtissues derived from its PDXs using InSphero's 3D cell culture solutions.
Science Exchange is providing its R&D service marketplace to QB3, the University of California incubator for life sciences startups.
Forge Therapeutics and Evotec have launched a discovery platform to develop novel antibiotics targeting metalloenzymes.
Janssen has developed a mobile toolkit for trial supply management and patient engagement that can track adherence to each pill.
It can be seriously disruptive when the site investigator for your trial leaves or decides to step down, but new recommendations from the Clinical Trials…
Elligo Health Research will test a harmonized real-word data model built by the FDA.